Certain regulatory RNAs are involved in cancer cell movement and metastases. On...
Certain regulatory RNAs are involved in cancer cell movement and metastases. On the right, cancer cells are on the move with long, stiff actin filaments (in green) acting like fingers to help it move. Paxillin (red) collects in patches on the cell’s edge, sticking it to a surface. On the left, cells lacking one such regulatory RNA, MaTAR25, are flat. Actin filaments and paxillin are disrupted (speckles instead of filaments or patches), so cells are unable to move efficiently, reducing their ability to escape a tumor and metastasize.

Images: Kung-Chi Chang/Spector lab

News • Stepstone for new treatments

Regulatory RNAs promote breast cancer metastasis

Cold Spring Harbor Laboratory (CSHL) scientists have discovered a gene-regulating snippet of RNA that may contribute to the spread of many breast cancers.

In animal experiments, the researchers could reduce the growth of metastatic tumors with a molecule designed to target that RNA and trigger its destruction. The same strategy, they say, could be used to develop a new breast cancer treatment for patients.

The study, led by CSHL Professor and Director of Research David Spector, was reported in the journal Nature Communications

In 2016, Spector and colleagues identified dozens of RNA molecules that were more prevalent in breast cancer cells than in noncancerous cells of the same type. All were long, non-coding RNAs (lncRNAs)—RNA molecules that do not encode proteins and are thought to play various regulatory roles inside cells. The current study investigated how one of these, Mammary Tumor-Associated RNA 25 (MaTAR 25), impacted breast cancer cells’ behavior in mice.

Experiments by Kung-Chi Chang, a graduate student in Spector’s lab, indicate the molecule contributes to cancer’s progression in several ways—revving up cells’ growth as well as their ability to migrate and invade tissue. These effects may be due to changes in the activity of the tensin1 gene, which the team found is one of MaTAR 25’s targets. Tensin1 helps connect a cell’s internal cytoskeleton to the external matrix that surrounds it and is therefore positioned to influence a cell’s movement as well as its growth-regulating pathways.

To eliminate MaTAR 25, the researchers designed a small piece of nucleic acid that recognizes and binds to its sequence. Once bound, that molecule, known as an antisense oligonucleotide, alerts an enzyme inside cells to destroy the lncRNA. When the researchers injected this molecule into the bloodstream of mice, it reached tumor cells and degraded most of the MaTAR 25, with dramatic effects. Spector said: “When we did histology on the tumors, we found that they were very necrotic, meaning there was a lot of cell death after this RNA was degraded. And obviously, that’s an important finding, but equally, if not more important, we found a very significant reduction in metastasis to the lungs. So this, you know, really gave us some very exciting data that this RNA molecule has some potential as a therapeutic target.”

Spector’s team found that high levels of an analogous RNA called LINC01271 are associated with more aggressive disease in patient breast tumors. They are now investigating whether an antisense oligonucleotide that targets LINC01271 can interfere with tumor growth and metastases in patient-derived breast cancer models.


Source: Cold Spring Harbor Laboratory (CSHL)

23.12.2020

Read all latest stories

Related articles

Photo

News • Tumour plasticity

Why breast cancer metastases spread to the bone

A protein vital in determining the organs affected by metastasis has been identified by Swiss researchers. This could lead to the development of therapeutic approaches to suppress metastasis.

Photo

News • Screening performance

MRI reduces breast cancer deaths in women with 3 risk genes

Annual MRI screenings starting at ages 30-35 may reduce breast-cancer mortality by more than 50% among women who carry certain genetic changes in three genes, according to a new modeling analysis.

Photo

News • BRCA and prostate, pancreatic cancers

Faulty 'breast cancer gene' BRCA also dangerous for men

Faulty versions of the BRCA1 and BRCA2 genes are well known to increase the risk of breast and ovarian cancer. Now, they have been linked to several other cancers, including those that affect men.

Related products

AB-CT – Advanced Breast-CT – nu:view

Mammo CT

AB-CT – Advanced Breast-CT – nu:view

AB-CT – Advanced Breast-CT GmbH
CliniSys | MIPS – MIPS GLIMS genetics

LIS, Middleware, POCT

CliniSys | MIPS – MIPS GLIMS genetics

CliniSys | MIPS Deutschland GmbH
Fujifilm – Amulet Bellus II

Mammo Workstations

Fujifilm – Amulet Bellus II

FUJIFILM Europe GmbH
Fujifilm – AMULET Innovality

Tomosynthesis

Fujifilm – AMULET Innovality

FUJIFILM Europe GmbH
Fujifilm – AMULET Innovality Harmony

Tomosynthesis

Fujifilm – AMULET Innovality Harmony

FUJIFILM Europe GmbH
Subscribe to Newsletter